The Pharma Data

DECEMBER 21, 2020

Galidesivir treatment was associated with a more rapid decline in viral RNA levels in the respiratory tract in an apparent dose-dependent manner. About Galidesivir (BCX4430) Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

DrugBank

JANUARY 29, 2025

In certain cancers, the overexpression or constitutive activation of oncogenes , such as HER2, KRAS, or BRAF, can drive tumorigenesis by dysregulating key signaling pathways that govern cell growth, survival, and differentiation.

Therapies 52

Therapies DNA RNA Disease 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. For more than 150 years, we have worked to make a difference for all who rely on us.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

JANUARY 12, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland. The Swiss Federal Government has secured 7.5 CAMBRIDGE, Mass.–(BUSINESS About Moderna.

Vaccine 52

Vaccine RNA Clinical Trials Science 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 .–(BUSINESS WIRE)–Dec. 8, 2020– Moderna, Inc.,

Vaccine 40

Vaccine RNA Clinical Trials Government 40

The Pharma Data

DECEMBER 3, 2020

The company has not revealed where the problems occurred, but vaccines typically require materials that include antiviral agents, antiseptic liquids, sterile water, and the nucleic acids that make up the RNA of the virus that is used in the mRNA vaccines. A third German site is being built. Given the problems the U.S.

Vaccine 52

Vaccine Government RNA FDA 52

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. government by the end of December 2020. government has agreed to purchase supply of the Moderna COVID-19 Vaccine under U.S. 20, 2020 02:44 UTC. CAMBRIDGE, Mass.–( 75A50120C00034. W911QY-20-C-0100.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

Drug Target Review

APRIL 3, 2024

By actively addressing these challenges and implementing supportive measures, organisations, governments and institutions can create a more inclusive and equitable environment for women in natural sciences. in North America) in late 2017.

Science 106

Science Clinical Development Treatment DNA 106

Molecule Blog

MARCH 17, 2023

Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies. In return, they receive governance tokens in the organization, granting them voting rights on proposals, such as which research projects to fund or how to support a project.

Engineering 52

Engineering Research Clinical Trials Government 52

Drug Target Review

SEPTEMBER 28, 2023

Researchers were able to use our synthetic RNA controls as a reference to verify and validate assays. We participate at the federal and state government levels to help develop a guiding path for biomanufacturing curriculums for two-year degrees.

DNA 116

DNA Organic Chemistry Science Virus 116

Drug Target Review

JUNE 11, 2024

My PhD work was focused on understanding how different helicases – small machines that unwind DNA and RNA – work and characterise them using biochemistry and biophysics tools. Governments could also work on educating parents to overcome some unconscious biases, for instance when choosing the toys their kids play with.

Engineering 65

Engineering Science Molecular Biology Doctors 65

The Pharma Data

MARCH 5, 2021

This will be adapted to the needs of messenger RNA vaccine production for CureVac’s CVnCoV, the manufacturing of which is highly complex. Production will take place in a new high-tech production facility that was already under construction at the Novartis Kundl, Austria site.

Vaccine 52

Vaccine Production Biosimilars Hospitals 52

The Pharma Data

JANUARY 17, 2021

About STP705 Sirnaomics’ leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-?1 1 and COX-2 gene expression.

Treatment 52

Treatment Trials FDA Approval RNA 52

The Pharma Data

NOVEMBER 16, 2020

government, as well as global stakeholders to be prepared for distribution of mRNA-1273, in the event that it receives an Emergency Use Authorization and/or similar global authorizations. government has agreed to provide up to $1.525 billion to purchase supply of mRNA-1273 under U.S. government’s potential purchases of mRNA-1273.

Vaccine 52

Vaccine FDA Clinical Trials Pharmacy 52

The Pharma Data

NOVEMBER 16, 2020

It combines Moderna’s mRNA (messenger RNA) delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID scientists. The mRNA-1273 vaccine candidate was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc.,

Clinical Trials 52

Clinical Trials Vaccine Trials FDA Approval 52

Elrig

JUNE 18, 2024

Vitae, non-profit programme of CRAC, is the global leader in supporting the career and professional development of researchers, experienced in working with governments and over 200 institutions in 23 countries. CRAC is a charity and was founded in 1964.

Science 52

Science Therapies RNA Research 52

The Pharma Data

SEPTEMBER 1, 2020

In general, antigen tests have a high specificity, though are not as sensitive as molecular tests that amplify the target viral DNA or RNA sequence in order to generate a quantifiable signal to indicate the presence of the virus in a sample.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

JANUARY 4, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Vaccine 40

Vaccine FDA RNA Clinical Trials 40

The Pharma Data

JANUARY 13, 2021

” The Johnson & Johnson vaccine also would be hardier than either of the already approved vaccines because it relies on DNA technology rather than messenger RNA to prompt an immune system response. If you only have to give one dose, that would be great.” The pharmaceutical giant pledged in its $1 billion contract with the U.S.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

NOVEMBER 16, 2020

government, as well as global stakeholders to be prepared for distribution of mRNA-1273, in the event that it receives an EUA and similar global authorizations. government has agreed to provide up to $1.525 billion to purchase supply of mRNA-1273 under U.S. CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Nov.

Vaccine 52

Vaccine Clinical Trials FDA Disease 52

The Pharma Data

DECEMBER 10, 2020

Both vaccination regimens resulted in complete protection from subsequent viral ‘challenge’ as reflected by reductions in viral RNA levels that were below the level of detection by day seven post-challenge compared to controls. The agreement also details the structure of shared governance of the joint collaboration.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

APRIL 30, 2021

Under the multi-year agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies directed to targets specified by AbbVie. AbbVie and Caribou Biosciences, Inc., Full-Year 2021 Outlook.

FDA 40

FDA Production Treatment International 40

Broad Institute

NOVEMBER 20, 2024

This work illustrates that you really have to integrate the spatial relationships governing a given organ into your thinking, and we hope our study provides a platform and framework that helps put both previous and future discoveries in context,” Mayassi said. Xavier is the director of Broad’s Immunology Program, as well as the Kurt J.

Regulations 84

Regulations Immune Response Molecular Biology Disease 84

Broad Institute

OCTOBER 4, 2023

Today, scientists use such reactions to produce the customizable DNA and RNA molecules that enable genetic sequencing, drug and vaccine development, pathogen tests, cancer diagnostics, and more. It is because we had the Fellowship that we could buy our very first DNA and RNA synthesizer in the lab.”

DNA 52

DNA RNA Science Protein Expression 52

The Pharma Data

MAY 31, 2022

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax TM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna, Inc., About Moderna.

Vaccine 52

Vaccine Marketing RNA Science 52

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. When it enters the cell, it is converted into RNA-like building blocks.

RNA 52

RNA Virus Clinical Trials Drugs 52

The Pharma Data

NOVEMBER 24, 2020

Oxlumo works by degrading HAO1 messenger RNA and reducing the synthesis of GO, which inhibits hepatic production of oxalate – the toxic metabolite responsible for the clinical manifestations of PH1. HAO1 encodes glycolate oxidase (GO), an enzyme upstream of the disease-causing defect in PH1.

FDA Approval 52

FDA Approval Treatment FDA RNA 52

Codon

APRIL 19, 2023

government found out about it. A lawsuit alleged that Black’s company had failed “to disclose substantial payments to officials of foreign governments in order to secure favorable treatment.” deposed a democratically-elected government in Guatemala at the behest of the same company.) million per year.

DNA 52

DNA RNA Engineering Regulations 52

Codon

APRIL 19, 2023

government found out about it. A lawsuit alleged that Black’s company had failed “to disclose substantial payments to officials of foreign governments in order to secure favorable treatment.” deposed a democratically-elected government in Guatemala at the behest of the same company.) million per year.

DNA 52

DNA RNA Engineering Regulations 52

Codon

JULY 27, 2023

A LEGO robot , made by undergraduate students at Arizona State University, pours sucrose gradients (a tube with dense liquid at the bottom, and less dense liquid at the top), which are used to separate, say, proteins from RNA by spinning them really fast in centrifuges. How do transcription factors couple up with the correct RNA molecule?

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

A LEGO robot , made by undergraduate students at Arizona State University, pours sucrose gradients (a tube with dense liquid at the bottom, and less dense liquid at the top), which are used to separate, say, proteins from RNA by spinning them really fast in centrifuges. How do transcription factors couple up with the correct RNA molecule?

Therapies 52

Therapies RNA DNA Engineering 52

The Pharma Data

AUGUST 30, 2021

As the first and only small interfering RNA to provide effective and sustained LDL-C reduction, Leqvio helps manage a critical cardiovascular risk factor for ASCVD. Leqvio is the first and only approved small interfering RNA (siRNA) LDL-C-lowering treatment in Europe 6,7. It is currently under review by the U.S.

RNA 52

RNA Disease Trials Therapies 52

The Pharma Data

AUGUST 29, 2020

This analysis confirms that as a small interfering RNA (siRNA), inclisiran provides a remarkably consistent treatment profile. Inclisiran will potentially be the first and only LDL-C-lowering small-interfering RNA (siRNA) treatment. 30% reduction of their LDL-C levels with a mean reduction of 54.1% from baseline (observed values) 2­.

Treatment 52

Treatment Disease Therapies Trials 52

The Pharma Data

AUGUST 31, 2021

Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a 6-monthly maintenance dose ‡ , in the community setting. About inclisiran.

Therapies 52

Therapies Disease RNA Clinical Trials 52

The Pharma Data

FEBRUARY 25, 2022

“SARS-CoV-2 produces long proteins, called polyproteins, from its RNA genome that must be cleaved into individual proteins by these proteases in an ordered fashion leading to the formation of functional virus enzymes and proteins to start virus replication once it enters a cell,” Murakami explained.

FDA Approval 52

FDA Approval Molecular Biology FDA Virus 52

The Pharma Data

AUGUST 3, 2021

The company and MiNA Therapeutics Limited announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. and international governments and near-term expiry dates of COVID-19 antibodies. Business Development/Other Developments.

Production 52

Production Marketing Research DNA 52